Main Street Group LTD Sells 232 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Main Street Group LTD lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 618 shares of the biopharmaceutical company’s stock after selling 232 shares during the period. Main Street Group LTD’s holdings in Gilead Sciences were worth $57,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Man Group plc lifted its stake in Gilead Sciences by 38.7% in the fourth quarter. Man Group plc now owns 873,179 shares of the biopharmaceutical company’s stock valued at $80,656,000 after buying an additional 243,567 shares in the last quarter. Nissay Asset Management Corp Japan ADV raised its holdings in shares of Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company’s stock worth $26,750,000 after acquiring an additional 14,009 shares during the period. NorthRock Partners LLC lifted its position in Gilead Sciences by 280.3% in the 4th quarter. NorthRock Partners LLC now owns 11,207 shares of the biopharmaceutical company’s stock valued at $1,035,000 after acquiring an additional 8,260 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in Gilead Sciences by 16.2% in the 4th quarter. Nuveen Asset Management LLC now owns 5,208,321 shares of the biopharmaceutical company’s stock worth $481,093,000 after purchasing an additional 724,493 shares during the period. Finally, Measured Risk Portfolios Inc. bought a new position in Gilead Sciences during the 4th quarter worth about $67,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Bank of America upped their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price objective on the stock. Piper Sandler increased their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, BMO Capital Markets raised their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now directly owns 168,174 shares of the company’s stock, valued at $17,893,713.60. This represents a 1.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 22,929 shares of company stock valued at $2,644,895 in the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Down 2.3%

GILD stock opened at $101.43 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The business’s 50 day simple moving average is $106.71 and its 200 day simple moving average is $99.51. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $126.30 billion, a PE ratio of 274.14, a PEG ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.32) earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.12%. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.